Providence Capital Advisors’s Amedisys AMED Stock Holding History

Providence Capital Advisors’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10	Closed	-$2K	–	292
2022 Q1	$2K	Buy	+10	New	+$1.49K	﹤0.01%	337

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Providence Capital Advisors's AMED Position: Q2 2022 in Review

Providence Capital Advisors sold out of Amedisys (AMED) in Q2 2022, closing a stake of 10 shares — an estimated $2K sold.

Providence Capital Advisors first reported a position in AMED in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 288 funds tracked by Wall St. Rank hold AMED as of Q2 2022.

Providence Capital Advisors reported no remaining Amedisys position as of Q2 2022 after selling out during the quarter.
Providence Capital Advisors sold 10 Amedisys shares in Q2 2022, an estimated $2K.
Providence Capital Advisors first reported a position in Amedisys in Q1 2022 and held it in 1 quarter.
Providence Capital Advisors's Amedisys position peaked at $2K in Q1 2022.
288 funds tracked by Wall St. Rank held Amedisys as of Q2 2022.

Based on Providence Capital Advisors's 13F filing for Q2 2022, filed 9 Aug 2022.